[骨质疏松药物的发展-过去,现在和未来-]

Clinical calcium Pub Date : 2017-01-01
Shinya Tanaka
{"title":"[骨质疏松药物的发展-过去,现在和未来-]","authors":"Shinya Tanaka","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>From 1990s to 2000s, new drugs for osteoporosis have been developed, and the bone metabolism researches have livened up. In those days, many a people gathered to the meeting from many countries, and the each booth of pharmaceutics was proud of its preeminence. The dedications by the society and its members have had osteoporosis diagnostics developed, the anchor drugs become prevalent, and the number of fractures reduced. Although the brilliant effects of Romosozumab and Abaloparatide were presented in the meeting held this year, the members had to accept the convergence state of new drug developments. But some problems have been still left unsolved, the development of more effective drugs to prevent fragile bone fractures without any adverse events, the safety of long term use of the osteoporosis drugs, and the effectiveness of drugs to prevent from fractures of the oldest old people.</p>","PeriodicalId":502100,"journal":{"name":"Clinical calcium","volume":"27 1","pages":"137-141"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Development of osteoporosis drugs -the past, the present and the future-.]\",\"authors\":\"Shinya Tanaka\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>From 1990s to 2000s, new drugs for osteoporosis have been developed, and the bone metabolism researches have livened up. In those days, many a people gathered to the meeting from many countries, and the each booth of pharmaceutics was proud of its preeminence. The dedications by the society and its members have had osteoporosis diagnostics developed, the anchor drugs become prevalent, and the number of fractures reduced. Although the brilliant effects of Romosozumab and Abaloparatide were presented in the meeting held this year, the members had to accept the convergence state of new drug developments. But some problems have been still left unsolved, the development of more effective drugs to prevent fragile bone fractures without any adverse events, the safety of long term use of the osteoporosis drugs, and the effectiveness of drugs to prevent from fractures of the oldest old people.</p>\",\"PeriodicalId\":502100,\"journal\":{\"name\":\"Clinical calcium\",\"volume\":\"27 1\",\"pages\":\"137-141\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical calcium\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical calcium","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

从20世纪90年代到21世纪初,治疗骨质疏松症的新药不断开发,骨代谢研究活跃起来。那时,来自世界各国的人聚集在一起,每个制药展位都以自己的卓越而自豪。在协会及其成员的奉献下,骨质疏松症诊断方法得以发展,锚定药物变得普遍,骨折数量减少。虽然在今年的会议上,Romosozumab和Abaloparatide的辉煌效果得到了展示,但成员们不得不接受新药开发的趋同状态。但是一些问题仍然没有得到解决,如开发更有效的药物来预防脆弱的骨折而没有任何不良事件,骨质疏松药物长期使用的安全性,以及预防最年长老年人骨折的药物的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Development of osteoporosis drugs -the past, the present and the future-.]

From 1990s to 2000s, new drugs for osteoporosis have been developed, and the bone metabolism researches have livened up. In those days, many a people gathered to the meeting from many countries, and the each booth of pharmaceutics was proud of its preeminence. The dedications by the society and its members have had osteoporosis diagnostics developed, the anchor drugs become prevalent, and the number of fractures reduced. Although the brilliant effects of Romosozumab and Abaloparatide were presented in the meeting held this year, the members had to accept the convergence state of new drug developments. But some problems have been still left unsolved, the development of more effective drugs to prevent fragile bone fractures without any adverse events, the safety of long term use of the osteoporosis drugs, and the effectiveness of drugs to prevent from fractures of the oldest old people.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信